BiotechTube

Brodalumab 210mg SC

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Psoriasis Vulgaris

Conditions

Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma

Trial Timeline

Jul 4, 2016 → Jul 24, 2017

NCT ID
NCT04183881

About Brodalumab 210mg SC

Brodalumab 210mg SC is a approved stage product being developed by Kyowa Kirin for Psoriasis Vulgaris. The current trial status is completed. This product is registered under clinical trial identifier NCT04183881. Target conditions include Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris.

What happened to similar drugs?

20 of 20 similar drugs in Psoriasis Vulgaris were approved

Approved (20) Terminated (3) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Ilumya Injectable ProductSun PharmaceuticalApproved
✅TildrakizumabSun PharmaceuticalApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04183881ApprovedCompleted

Competing Products

20 competing products in Psoriasis Vulgaris

See all competitors
ProductCompanyStageHype Score
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + PlaceboDr. Reddy's LaboratoriesPhase 2
32
Ixekizumab + PlaceboEli LillyPhase 2
35
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
21
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
27
IxekizumabEli LillyPhase 3
40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
40
Placebo + BaricitinibEli LillyPhase 2
35
CT-P43 + StelaraCelltrionPhase 3
40
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
AMG 139AstraZenecaPhase 1
29
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 2
35
Tacrolimus CreamAstellas PharmaPhase 3
40
alefaceptAstellas PharmaPhase 3
40
peficitinib + PlaceboAstellas PharmaPhase 2
35
AlefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40